Vaccine trial for Alzheimer's clears key hurdle

June 7, 2012

A vaccine which revives a promising but long-abandoned path to thwart Alzheimer's disease has cleared a key safety hurdle in human trials, researchers say.

In a small-scale test, the formula was found to be safe and primed the body's frontline defences against protein deposits in the brain that are associated with the catastrophic disease.

Swedish doctors report the results in Wednesday's issue of the journal Lancet Neurology, saying that the way is now open for wider trials.

The prototype vaccine, called CAD106, is a new exploration of traditional vaccine engineering.

In this approach, the pathogen that causes a disease is used to teach the immune system to identify an intruder and attack it.

In Alzheimer's, one of the enemies is a called amyloid beta peptide, which accumulates in plaques in the brain, although exactly how it works remains unclear.

A decade ago, doctors launched a first attempt at an amyloid beta vaccine, called AN1792.

But they were forced to abandon it at the second of the three-phase trial process after six percent of the volunteers fell ill with meningoencephalitis, an inflammation of the brain.

The suspected reason was that AN1792 activated called that attacked the .

The new vaccine uses a smaller fragment of the protein and combines it with a booster, called an , intended to prevent T-cell activation.

After lengthy trials in the lab, a team led by Bengt Winblad of the Karolinska Institutet's Alzheimer's Disease Research Centre, tested the vaccine on 46 volunteers aged 50 to 80, diagnosed with mild to moderate Alzheimer's.

A "control" group of 12 patients received a harmless formula, called a placebo, as a comparison.

The group was studied over 52 weeks and given a follow-up examination two years later.

Eighty-two percent of the patients who received CAD106 developed antibodies, a sign that the had responded to the dangerous protein.

Overall, nine patients had episodes of ill health during the trial, but investigations showed these were unrelated to the drug, and none entailed meningoencephalitis.

The next step after this Phase 1 safety trial should be a larger test, possibly with modifications of the dose, to see if the vaccine works, says the study.

Around 26 million people around the world have Alzheimer's, which remains an incurable and progressive disease characterised by memory loss and dementia.

The toll by 2050 is likely to be 115 million, according to figures cited in the journal.

Explore further: Alzheimer's vaccine cures memory of mice

More information: "Safety, tolerability, and antibody response of active Aβimmunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study", Bengt Winblad, Niels Andreasen, Lennart Minthon, Annette Floesser, Georges Imbert, Thomas Dumortier, R Paul Maguire, Kaj Blennow, Joens Lundmark, Matthias Staufenbiel, Jean-Marc Orgogozo & Ana Graf, Lancet Neurology, online first 6 June 2012, doi:10.1016/S1474-4422(12)70140-0

Related Stories

Alzheimer's vaccine cures memory of mice

December 9, 2011
(Medical Xpress) -- A vaccine that slows the progression of Alzheimer's disease and other types of dementia has been developed by researchers at the University of Sydney's Brain and Mind Research Institute (BMRI).

Recommended for you

Lifestyle changes to stave off Alzheimer's? Hints, no proof

July 20, 2017
There are no proven ways to stave off Alzheimer's, but a new report raises the prospect that avoiding nine key risks starting in childhood just might delay or even prevent about a third of dementia cases around the world.

Blood test identifies key Alzheimer's marker

July 19, 2017
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their ...

Steering an enzyme's 'scissors' shows potential for stopping Alzheimer's disease

July 19, 2017
The old real estate adage about "location, location, location" might also apply to the biochemical genesis of Alzheimer's disease, according to new research from the University of British Columbia.

Brain scans may change care for some people with memory loss

July 19, 2017
Does it really take an expensive brain scan to diagnose Alzheimer's? Not everybody needs one but new research suggests that for a surprising number of patients whose memory problems are hard to pin down, PET scans may lead ...

Can poor sleep boost odds for Alzheimer's?

July 18, 2017
(HealthDay)— Breathing problems during sleep may signal an increased risk for Alzheimer's disease, a trio of studies suggests.

Hearing is believing: Speech may be a clue to mental decline

July 17, 2017
Your speech may, um, help reveal if you're uh ... developing thinking problems. More pauses, filler words and other verbal changes might be an early sign of mental decline, which can lead to Alzheimer's disease, a study suggests.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.